Market analysts have been trying to read the tea leaves regarding Intercept Pharmaceuticals, Inc.’s prospects for getting obeticholic acid (OCA) refiled for US approval in non-alcoholic steatohepatitis for months now, and while the firm’s fourth quarter/full-year 2020 earnings call on 25 February offered assurances about refiling the new drug application by year’s end, those same analysts don’t seem fully convinced.
New CEO Jerome Durso, promoted from chief operating officer on 1 January as long-time former CEO Mark Pruzanski retired and took a seat on the Intercept board, opened the investor...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?